Literature DB >> 30874903

Controversies in the Therapy of Low-Grade Gliomas.

Ivan D Carabenciov1, Jan C Buckner2.   

Abstract

OPINION STATEMENT: In the context of the new WHO classification system, all low-grade gliomas must have an IDH mutation, with or without 1p/19q codeletion. Upon discovery of the tumor, maximal safe surgical resection is the most appropriate first step due to the current inability to differentiate between IDH mutant and IDH wild-type tumors by imaging alone. In the postoperative setting, based on the synthesis and interpretation of the available data, we recommend utilizing conventional radiation therapy and PCV in all high-risk-low-grade gliomas. For patients felt to be in a low risk category, we recommend maintaining a low threshold to initiate treatment. In the setting of tumor recurrence, consideration of all treatment options is reasonable, but treatment with alkylator therapy has the strongest supporting data.

Entities:  

Keywords:  Controversy; IDH mutation; Low-grade glioma; PCV; Temozolomide

Year:  2019        PMID: 30874903     DOI: 10.1007/s11864-019-0625-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  53 in total

1.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study.

Authors:  E Shaw; R Arusell; B Scheithauer; J O'Fallon; B O'Neill; R Dinapoli; D Nelson; J Earle; C Jones; T Cascino; D Nichols; R Ivnik; R Hellman; W Curran; R Abrams
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

2.  Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.

Authors:  M J van den Bent; D Afra; O de Witte; M Ben Hassel; S Schraub; K Hoang-Xuan; P-O Malmström; L Collette; M Piérart; R Mirimanoff; A B M F Karim
Journal:  Lancet       Date:  2005 Sep 17-23       Impact factor: 79.321

3.  Phase II trial of temozolomide in patients with progressive low-grade glioma.

Authors:  Jennifer A Quinn; David A Reardon; Allan H Friedman; Jeremy N Rich; John H Sampson; James M Provenzale; Roger E McLendon; Sridharan Gururangan; Darell D Bigner; James E Herndon; Nicholas Avgeropoulos; Jonathan Finlay; Sandra Tourt-Uhlig; Mary Lou Affronti; Brandon Evans; Valerie Stafford-Fox; Sara Zaknoen; Henry S Friedman
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

4.  Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

Authors:  Stephanie E Combs; Christoph Thilmann; Lutz Edler; Jürgen Debus; Daniela Schulz-Ertner
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

5.  Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.

Authors:  M Brada; L Viviers; C Abson; F Hines; J Britton; S Ashley; S Sardell; D Traish; A Gonsalves; P Wilkins; C Westbury
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

6.  Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.

Authors:  A Pace; A Vidiri; E Galiè; M Carosi; S Telera; A M Cianciulli; P Canalini; D Giannarelli; B Jandolo; C M Carapella
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

Review 7.  The neurocognitive effects of radiation in adult low-grade glioma patients.

Authors:  Paul D Brown; Jan C Buckner; Joon H Uhm; Edward G Shaw
Journal:  Neuro Oncol       Date:  2003-07       Impact factor: 12.300

8.  Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial.

Authors:  Edward G Shaw; Brian Berkey; Stephen W Coons; Dennis Bullard; David Brachman; Jan C Buckner; Keith J Stelzer; Geoffrey R Barger; Paul D Brown; Mark R Gilbert; Minesh Mehta
Journal:  J Neurosurg       Date:  2008-11       Impact factor: 5.115

9.  Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

Authors:  M J van den Bent; M J B Taphoorn; A A Brandes; J Menten; R Stupp; M Frenay; O Chinot; J M Kros; C C D van der Rijt; Ch J Vecht; A Allgeier; T Gorlia
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

10.  Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas.

Authors:  Justin S Smith; Edward F Chang; Kathleen R Lamborn; Susan M Chang; Michael D Prados; Soonmee Cha; Tarik Tihan; Scott Vandenberg; Michael W McDermott; Mitchel S Berger
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

View more
  5 in total

Review 1.  Neuroplasticity of Glioma Patients: Brain Structure and Topological Network.

Authors:  Kun Lv; Xin Cao; Rong Wang; Peng Du; Junyan Fu; Daoying Geng; Jun Zhang
Journal:  Front Neurol       Date:  2022-05-13       Impact factor: 4.086

2.  Contralesional Structural Plasticity in Different Molecular Pathologic Subtypes of Insular Glioma.

Authors:  Zhenxing Huang; Gen Li; Zhenye Li; Shengjun Sun; Yazhuo Zhang; Zonggang Hou; Jian Xie
Journal:  Front Neurol       Date:  2021-04-14       Impact factor: 4.003

3.  Prognostic value of O 6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas.

Authors:  Keng Lam; Blaine S C Eldred; Bryan Kevan; Sean Pianka; Brittany A Eldred; Serendipity Zapanta Rinonos; William H Yong; Linda M Liau; Phioanh L Nghiemphu; Timothy F Cloughesy; Richard M Green; Albert Lai
Journal:  Neurooncol Adv       Date:  2022-03-01

4.  Risk factors for early progression of diffuse low-grade glioma in adults.

Authors:  Long Wang; Xuegang Li; Tunan Chen; Chao Zhang; Jiantao Shi; Hua Feng; Fei Li
Journal:  Chin Neurosurg J       Date:  2022-10-01

5.  Tumor Suppressor microRNA-138 Suppresses Low-Grade Glioma Development and Metastasis via Regulating IGF2BP2.

Authors:  Yang Yang; Xinyu Liu; Lulu Cheng; Li Li; Zhenyu Wei; Zong Wang; Gang Han; Xuefeng Wan; Zaizhong Wang; Jianhua Zhang; Chuanliang Chen
Journal:  Onco Targets Ther       Date:  2020-03-13       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.